Abstracts Archive - Page 108 of 2425 - ACR Meeting Abstracts

Abstract Number: 1204 • ACR Convergence 2024
Immunobased Profiling of Knee Osteoarthritis Patients to Predict Response to Regenerative Treatment with Autologous Blood-derivative Platelet-Rich Plasma Injection
Antonio Tonutti¹, Valentina Granata², Veronica Marrella², Cristina Sobacchi², Rita Ragusa³, Marzia Monferini³, Cristiano sconza³, Nicola rani⁴, Berardo Di Matteo⁵, Carlo Selmi⁶ and Angela Ceribelli⁵, ¹Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Italy, ²Humanitas Research Hospital and Institute for Genetic and Biomedical Research, Rozzano, Italy, ³Humanitas Research Hospital, Rozzano, Italy, ⁴Rizzoli Orthopaedic Institute, Bologna, Italy, ⁵Humanitas University and Humanitas Research Hospital, Rozzano, Italy, ⁶Department of Biomedical Sciences, Humanitas University, Rozzano, Italy
Background/Purpose: Osteoarthritis (OA) is a degenerative musculoskeletal disease causing chronic disability and elevated social costs worldwide. Its multifactorial origin contributes to different OA phenotypes and…
Abstract Number: 1232 • ACR Convergence 2024
Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes
Elizabeth Luce¹, Beth schneider² and Dianna cronin², ¹MyHealthTeam, San Francisco, CA, ²MyHealthTeams, San Francisco, CA
Background/Purpose: People living with psoriatic arthritis often struggle with the physical and mental health toll. Understanding the holistic impact of psoriatic arthritis is crucial to…
Abstract Number: 1135 • ACR Convergence 2024
Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Richard Warren¹, April W. Armstrong², Shinichi Imafuku³, Akimichi Morita⁴, Carle Paul⁵, Matthias Augustin⁶, Thierry Passeron⁷, Leon Kircik⁸, Eleni Vritzali⁸, Thomas Scharnitz⁹, Georgene Schroeder⁹, Subhashis Banerjee¹⁰ and Bruce Strober¹¹, ¹Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²University of California Los Angeles, Los Angeles, ³Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, ⁴Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵Toulouse University and CHU, Toulouse, France, ⁶Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁷Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Bristol Myers Squibb, Princeton, ¹⁰Bristol Myers Squibb, Princeton, NJ, ¹¹Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
Abstract Number: 1209 • ACR Convergence 2024
Time to Knee Replacement by Kellgren-Lawrence Grade and Presence of Frequent Knee Pain in Two Large and Diverse Longitudinal Cohorts: Data from MOST and OAI
Kent Kwoh¹, Rongrong Tang², Edward Bedrick³, Jeffery Duryea⁴, Zong-Ming Li², Jean Liew⁵, Xiaoxiao Sun⁶ and Tuhina Neogi⁵, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, University of Arizona College of Medicine - Tucson, Tucson, AZ, ³Department of Epidemiology andBiostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ
Background/Purpose: Receipt of knee replacement has been proposed by the FDA as a structural and symptom outcome for clinical trials of Disease Modifying Osteoarthritis Drugs…
Abstract Number: 1161 • ACR Convergence 2024
Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Adriana Miguel-Álvarez¹, luis M Amezcua Guerra², María L Loredo-Mendoza¹, Luis H. Silveira Torre³ and Angélica Vargas Guerrero⁴, ¹Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, ²Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ³Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁴Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico
Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…
Abstract Number: 1163 • ACR Convergence 2024
Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population
Aurélie Mourot¹, Beatrice Panuta¹, Juliette Charbonneau¹, Ange Mounkam Ngeuleu¹, Caroline Vo², Eric Rich³, Josiane Bourré-Tessier³, Edith Villeneuve³, Hélène Manganas³, Andréanne Gauthier³, Julie Morisset³, Sabrina Anh-Tu Hoa³ and Océane Landon-Cardinal³, ¹University of Montreal, Montreal, QC, Canada, ²Hôpital Charles Lemoyne, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
Background/Purpose: Antisynthetase syndrome (ASSD) is characterized by interstitial lung disease (ILD), myositis, polyarthritis, Raynaud’s phenomenon, dermatomyositis-like rash and mechanic’s hands. ILD may present with isolated…
Abstract Number: 1177 • ACR Convergence 2024
Supporting Implementation of Group Physical Therapy for Knee Osteoarthritis: Results of a Multisite Implementation Trial
Kelli Allen¹, Sara Webb², Livia Anderson², lauren Abbate³, Lindsay Ballengee⁴, Cynthia Coffman², Connor Drake⁵, Graham Cummin⁵, Helen Hoenig⁵, Jaime Hughes⁶, Nina Sperber⁵, Matthew Tucker⁵, Amy Webster⁵, Leah Zullig⁵, Courtney Van Houtven⁵ and Susan Hastings⁵, ¹University of North Carolina, Durham, NC, ²Durham VA Healthcare System, Durham, NC, ³VA Eastern Colorado, Denver, CO, ⁴Duke University, Durham, NC, ⁵Durham VA Healthcare System, Durham, ⁶Wake Forest University, Winston Salem
Background/Purpose: Prior research has shown that compared to individual PT, group-based physical therapy (Group PT) yields equivalent or greater improvement in outcomes for patients with…
Abstract Number: 1247 • ACR Convergence 2024
Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations
Sarah N. Ali¹, Dorothee Oberdhan¹, Michelle M. Richardson¹, Jordan Amorelli², Amanda Martini² and Jennifer Dandy², ¹Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, ²Real Chemistry, New York, NY
Background/Purpose: Patients with Sjögren’s Syndrome (SS) often undergo a prolonged and complex path to diagnosis and experience symptom, disease and treatment burdens with multiple co-morbid…
Abstract Number: 1145 • ACR Convergence 2024
Clinico-Immunological Profile and Treatment Outcomes of Clinically Significant Diaphragmatic Weakness in Patients with Idiopathic Inflammatory Myopathies: Results from the Largest Single-Center Cohort of 16 Cases
Siddharth Jain¹, Bhargavi Pridhivi², Adil Rashid Khan², Stanzin Spalkit², Manish Soneja², Mehar Chand Sharma², Sanjeev Sinha², Uma Kumar² and Naveet Wig², ¹All India Institute of Medical Sciences, New Delhi, Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Diaphragmatic myositis is rarely reported in patients with idiopathic inflammatory myopathy (IIM) but is associated with high morbidity and mortality. Epidemiology, spectrum of clinical…
Abstract Number: 1218 • ACR Convergence 2024
Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia
Seth Lederman¹, Lesley Arnold², Mary Kelley¹, Ben Vaughn³, Jean Engels¹ and Gregory Sullivan¹, ¹Tonix Pharmaceuticals, Inc, Chatham, NJ, ²University of Cincinnati College of Medicine, Cincinnati, OH, ³Rho, Inc, Chapel Hill, NC
Background/Purpose: Fibromyalgia (FM) is a nociplastic syndrome of chronic widespread pain, nonrestorative sleep, fatigue, cognitive dysfunction and mood symptoms. RESILIENT was a confirmatory Phase 3…
Abstract Number: 1007 • ACR Convergence 2024
Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis
Connor Buechler, Lindsey Wanberg, Nawang Singhe, Cody Rasner, Joseph McGrath, Ziou Jiang, Karen Baker-James and David Pearson, University of Minnesota, Minneapolis, MN
Background/Purpose: Dermatomyositis (DM) is associated with significant morbidity and mortality due to disease-related progressive interstitial lung disease (ILD) and malignancy. However, little is known about…
Abstract Number: 1183 • ACR Convergence 2024
The Effectiveness of Orthosis for the Management of Hand Osteoarthritis-a Systemic Review and Meta-analysis
Nouf Alhammadi¹, Hanan Alqahtani² and Bagrat Hakobyan³, ¹HMG - Dr.Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia, ²University of toronto, Toronto, Canada, ³Independent researcher, Yerevan, Armenia
Background/Purpose: Hand osteoarthritis (OA) affects 11-33% of men and women in their 50s and 60s, significantly affecting the quality of life of those afflicted.Orthoses are…
Abstract Number: 1225 • ACR Convergence 2024
Fibromyalgia as a Potential Initial Presentation for Autoimmune Conditions
Qi Wang¹, Pratibha Chaudhary², Yu Chang³ and Megha Garg⁴, ¹Unity Hospital/Rochester Regional Health, Rochester, NY, ²Rochester General Hospital, Rochester, NY, ³National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁴Rochester Regional Health, Rochester, NY
Background/Purpose: Fibromyalgia is a non-autoimmune disease with widespread pain, severe fatigue, and sleep problems. There are limited studies examining the association between fibromyalgia and autoimmune…
Abstract Number: 1138 • ACR Convergence 2024
Association Between Long-Term Exposure to Fine Particles and Its Components and the Onset of Systemic Autoimmune Rheumatic Diseases in Quebec
Mareva geslin¹, Julien Vachon², Naizhuo Zhao³, Elhadji Anassour Laouan Sidi², Sonia Jean⁴, audrey smargiassi² and Sasha Bernatsky⁵, ¹Universite de Montreal, Montreal, QC, Canada, ²Université de Montréal, Montreal, QC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Institut national de santé publique du Québec, Montreal, QC, Canada, ⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Exposure to fine particles (PM2.5) has been associated with numerous health effects including with autoimmune rheumatic diseases (SARDs). While PM2.5 are composed of various…
Abstract Number: 1245 • ACR Convergence 2024
Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative
Stephanie Tancer¹, Basmah Al Dulaijan² and Puja Khanna³, ¹University of Michigan Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Gout is a chronic inflammatory arthritis induced by hyperuricemia and manifested by recurrent acute flares of debilitating joint pain when left untreated. Allopurinol is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].